Biomarkers as surrogate endpoints in cancer trials.

@article{Dunn2012BiomarkersAS,
  title={Biomarkers as surrogate endpoints in cancer trials.},
  author={Barbara K. Dunn and Esther G Akpa},
  journal={Seminars in oncology nursing},
  year={2012},
  volume={28 2},
  pages={
          99-108
        }
}
OBJECTIVES To define and discuss surrogate endpoint biomarkers, which are used in therapeutic trials as a substitute for the clinically meaningful "true" endpoint; and hence, may be used in answering cancer prevention questions in clinical trials evaluating drug/nutrient interventions for a number of common cancer sites. DATA SOURCES Literature, research articles. CONCLUSION Surrogate endpoint biomarkers offer greater efficiency in clinical studies because they may allow for the generation… CONTINUE READING
BETA

Topics from this paper.

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…